Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Business Roundup

July 14, 2018 | A version of this story appeared in Volume 96, Issue 29

Solvay will spend $56 million to modernize the cogeneration plant at its soda ash and sodium bicarbonate facility in Bernburg, Germany. The firm says the project will boost the site’s long-term competitiveness.

Arlanxeo will spend close to $100 million to modernize a polybutadiene facility in Brazil and a nitrile butadiene rubber facility in France. Arlanxeo is a synthetic rubber joint venture between Saudi Aramco and Lanxess.

AkzoNobel plans a second expansion of chloromethanes capacity in Frankfurt that will raise capacity by up to 50%. The firm recently completed a project there that boosted output of methylene chloride, chloroform, and carbon tetrachloride.

Ionic Materials,a maker of solid-state polymer battery electrolytes, has received an undisclosed investment from the venture arm of Hyundai Motor. The automaker says the start-up’s material will improve the safety, performance, and price of lithium-ion electric-vehicle batteries.

BASF plans to increase capacity for Irganox 1010, an antioxidant, by 40% at sites in Singapore and Switzerland. The sterically hindered phenolic antioxidant is added to a variety of plastics.

BASF has acquired Advanc3D Materials and Setup Performance, two European firms that make products for laser sintering. BASF says the purchases continue its expansion into the three-dimensional printing of plastics.

Otsuka Pharmaceutical will acquire Visterra for about $430 million. Otsuka says Visterra’s Hierotope technology enables the design of precision antibody-based therapies.

AstraZeneca, the University of Cambridge, and the Dutch firm Lumicks will form a center of excellence for dynamic single-molecule analysis. The center will be based around Lumicks’s C-Trap optical tweezers-fluo­rescence microscope.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.